BRISTOL-MYERS SQUIBB COMPANY Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO total compensation $21.88M; PEO compensation actually paid $16.86M; Other NEO average total compensation $9.22M.
- 2024-12-31: PEO total compensation $18.79M; PEO compensation actually paid $21.20M; Other NEO average total compensation $7.72M.
- 2023-12-31: Other NEO average total compensation $5.92M.
- 2022-12-31: PEO total compensation $20.05M; PEO compensation actually paid $35.06M; Other NEO average total compensation $7.00M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $21.88M | $16.86M | $9.22M | $7.32M | $105.00 | $198.00 | $7.05B | total revenues $48.19B | 2026-03-25 | |
| 2024-12-31 | $18.79M | $21.20M | $7.72M | $8.95M | $105.00 | $154.00 | -$8.95B | $48.30B | 2026-03-25 | |
| 2023-12-31 | $5.92M | -$525.20K | $91.00 | $142.00 | $8.03B | $45.01B | 2026-03-25 | |||
| 2022-12-31 | $20.05M | $35.06M | $7.00M | $10.87M | $123.00 | $139.00 | $6.33B | $46.16B | 2026-03-25 | |
| 2021-12-31 | $19.78M | $16.51M | $7.14M | $6.78M | $103.00 | $126.00 | $6.99B | $46.38B | 2026-03-25 | |
| 2024-12-31 | Dr. Chris Boerner | $18.79M | $21.20M | $7.72M | $8.95M | $105.00 | $154.00 | -$8.95B | total revenues $48.30B | 2025-03-26 |
| 2023-12-31 | $5.92M | -$525.20K | $91.00 | $142.00 | $8.03B | $45.01B | 2025-03-26 | |||
| 2022-12-31 | Dr. Giovanni Caforio | $20.05M | $35.06M | $7.00M | $10.87M | $123.00 | $139.00 | $6.33B | $46.16B | 2025-03-26 |
| 2021-12-31 | Dr. Giovanni Caforio | $19.78M | $16.51M | $7.14M | $6.78M | $103.00 | $126.00 | $6.99B | $46.38B | 2025-03-26 |
| 2020-12-31 | Dr. Giovanni Caforio | $20.15M | $17.64M | $7.05M | $6.29M | $100.00 | $102.00 | -$9.02B | $42.52B | 2025-03-26 |
| 2023-12-31 | Dr. Chris Boerner | $5.92M | -$525.20K | $91.00 | $142.00 | $8.03B | total revenues $45.01B | 2024-03-28 | ||
| 2022-12-31 | Dr. Giovanni Caforio | $7.00M | $10.87M | $123.00 | $139.00 | $6.33B | $46.16B | 2024-03-28 | ||
| 2021-12-31 | Dr. Giovanni Caforio | $7.14M | $6.78M | $103.00 | $126.00 | $6.99B | $46.38B | 2024-03-28 | ||
| 2020-12-31 | Dr. Giovanni Caforio | $7.05M | $6.29M | $100.00 | $102.00 | -$9.02B | $42.52B | 2024-03-28 | ||
| 2022-12-31 | Dr. Giovanni Caforio | $20.05M | $35.06M | $7.00M | $10.87M | $123.00 | $139.00 | $6.33B | Total Revenues $46.16B | 2023-03-23 |
| 2021-12-31 | Dr. Giovanni Caforio | $19.78M | $16.51M | $7.14M | $6.78M | $103.00 | $126.00 | $6.99B | $46.38B | 2023-03-23 |
| 2020-12-31 | Dr. Giovanni Caforio | $20.15M | $17.64M | $7.05M | $6.29M | $100.00 | $102.00 | -$9.02B | $42.52B | 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |